# An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311

> **NCT03531710** · PHASE2 · TERMINATED · sponsor: **United Neuroscience Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** UB-311
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03531710
- **Lead sponsor:** United Neuroscience Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-10
- **Primary completion:** 2019-10-31
- **Final completion:** 2019-10-31
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** United Neuroscience has decided to terminate V203-AD-EXT study based on a treatment assignment error
- **Last updated:** 2021-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531710, "An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03531710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*